• Distinct from other wound care products, Xeno-Skin™ offers the advantage of the inclusion of live cells, which allow it to temporarily incorporate with the patient’s own body, promoting more efficient, effective healing.

• The safety data from the current Phase I trial (severe burns, orphan indication) can be used to demonstrate safety and tolerability for a wide range of indications.

• A Phase II trial for efficacy is planned for 2021.

​

​

• Our Xeno-Genomics™ program is designed to achieve a "patient-specific" transplantation solution by designing the ideal porcine donor through specific, pragmatic genetic alterations.

• A broad array of cellular therapies could be derived to address countless other diseases, in addition to the conventional solid organ solutions such as heart, kidney,  and liver.

• Xeno-Genomics™ in vitro proof-of-concept data available in 2020.